Genomics of Prostate Cancer: Clinical Utility and Challenges
The studying of prostate cancer genomics is important for understanding prostate cancer biology, it can provide clinically relevant stratification into subtypes, the development of new prognostic and predictive markers in the context of precision medicine, and the development of new targeted ther...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2022-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/414429 |
| _version_ | 1797206585018155008 |
|---|---|
| author | Ivan Šamija Ana Fröbe |
| author_facet | Ivan Šamija Ana Fröbe |
| author_sort | Ivan Šamija |
| collection | DOAJ |
| description | The studying of prostate cancer genomics is important for understanding prostate
cancer biology, it can provide clinically relevant stratification into subtypes, the development of new
prognostic and predictive markers in the context of precision medicine, and the development of new
targeted therapies. Recent studies have provided detailed insight into genomics, epigenomics and proteomics
of prostate cancer, both primary and metastatic castration-resistant (mCRPC). Many mutations
have been discovered, both those that occur early in the carcinogenesis and progression as well as
those responsible for the resistance to therapy occurring later under the influence of treatment. A large
number of characteristic mutated signaling pathways has been identified, e.g. the mutations in DNA
repair pathway were found in 23% of mCRPC, which suggests potential response to PARP inhibitors.
Multifocality and intralesional genomic heterogeneity of prostate cancer make the clinical application
of genomics complicated. Although a great progress was made in understanding prostate cancer genomic,
and clinical studies related to its routine application are ongoing, prostate cancer genomics still
needs to find its standard wide routine application in patients with prostate cancer. |
| first_indexed | 2024-04-24T09:09:21Z |
| format | Article |
| id | doaj.art-4a5b5ba33d1449568d9265f7190e223b |
| institution | Directory Open Access Journal |
| issn | 0353-9466 1333-9451 |
| language | English |
| last_indexed | 2024-04-24T09:09:21Z |
| publishDate | 2022-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj.art-4a5b5ba33d1449568d9265f7190e223b2024-04-15T18:04:14ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512022-01-0161.Supplement 3869110.20471/acc.2022.61.s3.13Genomics of Prostate Cancer: Clinical Utility and ChallengesIvan Šamija0Ana Fröbe1Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; Department of Immunology, School of Dental Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, CroatiaThe studying of prostate cancer genomics is important for understanding prostate cancer biology, it can provide clinically relevant stratification into subtypes, the development of new prognostic and predictive markers in the context of precision medicine, and the development of new targeted therapies. Recent studies have provided detailed insight into genomics, epigenomics and proteomics of prostate cancer, both primary and metastatic castration-resistant (mCRPC). Many mutations have been discovered, both those that occur early in the carcinogenesis and progression as well as those responsible for the resistance to therapy occurring later under the influence of treatment. A large number of characteristic mutated signaling pathways has been identified, e.g. the mutations in DNA repair pathway were found in 23% of mCRPC, which suggests potential response to PARP inhibitors. Multifocality and intralesional genomic heterogeneity of prostate cancer make the clinical application of genomics complicated. Although a great progress was made in understanding prostate cancer genomic, and clinical studies related to its routine application are ongoing, prostate cancer genomics still needs to find its standard wide routine application in patients with prostate cancer.https://hrcak.srce.hr/file/414429Prostate CancerGenomicsTumor BiomarkersGenetic Heterogeneity |
| spellingShingle | Ivan Šamija Ana Fröbe Genomics of Prostate Cancer: Clinical Utility and Challenges Acta Clinica Croatica Prostate Cancer Genomics Tumor Biomarkers Genetic Heterogeneity |
| title | Genomics of Prostate Cancer: Clinical Utility and Challenges |
| title_full | Genomics of Prostate Cancer: Clinical Utility and Challenges |
| title_fullStr | Genomics of Prostate Cancer: Clinical Utility and Challenges |
| title_full_unstemmed | Genomics of Prostate Cancer: Clinical Utility and Challenges |
| title_short | Genomics of Prostate Cancer: Clinical Utility and Challenges |
| title_sort | genomics of prostate cancer clinical utility and challenges |
| topic | Prostate Cancer Genomics Tumor Biomarkers Genetic Heterogeneity |
| url | https://hrcak.srce.hr/file/414429 |
| work_keys_str_mv | AT ivansamija genomicsofprostatecancerclinicalutilityandchallenges AT anafrobe genomicsofprostatecancerclinicalutilityandchallenges |